Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Proarrhythmic Risk with Antipsychotic and Antidepressant Drugs

Implications in the Elderly

Abstract

The quinidine-like effects of some antidepressant drugs (particularly tricyclic antidepressants) and many antipsychotic drugs (particularly the phenothiazines) confound treatment of psychosis and depression in patients with major mental illness. This is especially true among elderly patients with existing risk factors for corrected QT (QTc) interval prolongation.

We used PubMed, previously reported review articles and the extensive personal files of the authors to identify cases of subjects aged ≥60 years who developed QTc interval prolongation, polymorphic ventricular tachycardia (PVT)/torsade de pointes (TdP) and/or sudden cardiac death while taking antipsychotic or antidepressant drugs or a combination of these medications. We identified 37 patients who had taken, in total, 46 antipsychotic or antidepressant drugs.

Our most striking finding was that almost four-fifths of our cases involved women. When the 14 critically ill subjects receiving haloperidol intravenously were excluded, 91.3% of our subjects were women. Almost three-quarters of our study subjects had cardiovascular disease.

Intravenous administration of haloperidol in the critically ill and profoundly agitated elderly warrants particular comment. Of the 14 subjects in this category identified, six were men and eight were women. In 13 cases, the drug dose far exceeded the 2 mg necessary to produce an antipsychotic effect. These clinicians were using an agent to achieve sedation that usually requires very high doses in the critically ill and profoundly agitated elderly to achieve this effect.

Inclusion criteria for our literature review required antipsychotic and/or antidepressant drug-induced QTc interval prolongation. Even so, our finding that 31 of our 37 subjects developed PVT is sobering. However, the reader should not conclude that drug-induced QTc interval prolongation is highly predictive of PVT or its TdP subtype. All of our study subjects had at least two risk factors for TdP, with age and sex being the most common. We included the rare case of a patient with congenital long QT syndrome who developed further lengthening of the QTc interval and TdP when prescribed an antidepressant drug well known to produce QTc interval prolongation.

We conclude with recommendations for clinicians not expert in the specialty of cardiology to deal with the many questions raised in this review. Specifically, such clinicians treating elderly patients with antipsychotic and antidepressant drugs that may prolong the QTc interval should aggressively obtain a baseline ECG for elderly female patients with additional risk factors such as personal or family history of pre-syncope or syncope, electrolyte disturbances or cardiovascular disease. Elderly male patients are also subject to QTc interval prolongation when such risk factors are present. It is important that the clinicians themselves inspect ECGs. If the QT interval is more than half the RR interval, QTc interval prolongation is likely to be present. In such cases, a cardiology colleague interested in QTc interval issues and TdP should be asked to review the ECG. Finally, nothing in our recommendations replaces meticulous attention to US FDA guidelines in the package insert of each drug.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Table I
Fig. 3
Fig. 4
Fig. 5
Table II
Table III

References

  1. 1.

    Vieweg WVR, Nicholson CS. Antidepressant drugs and the cardiovascular system. Med Update Psychiatrists 1996; 1: 154–60

  2. 2.

    Vieweg WVR, Nicholson CS. Torsade de pointes ventricular tachycardia, QT interval, and psychotropic drugs. Med Update Psychiatr 1997; 2(2): 48–54

  3. 3.

    Vieweg V, Driscoll R, Silber C. Long-term cardiovascular safety of sertindole. 49th Institute of Psychiatric Services; 1997 Oct 24–28; Washington, DC

  4. 4.

    Khan SP, Dahlvani S, Vieweg WVR, et al. Electrocardiographic QT interval in a geropsychiatric inpatient population: a preliminary study. Med Psychiatr 1998; 1: 71–4

  5. 5.

    Vieweg WVR. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. J Clin Psychiatry 2002; 63Suppl. 9: 18–24

  6. 6.

    Vieweg WVR. Strategies to prevent fatal arrhythmias with antipsychotics. Curr Psychiatry 2002; 1(5): 10–21

  7. 7.

    Ames D, Camm J, Cook P, et al. Minimizing the risks associated with significant QTc prolongation in people with schizophrenia: a consensus statement by the Cardiac Safety in Schizophrenia Group. Australas Psychiatry 2002 Jun; 10(2): 115–24

  8. 8.

    Vieweg WVR, McDaniel NL. Drug-induced QT interval prolongation and torsade de pointes in children and adolescents: part I of a four-part series. Child Adolesc Psychopharmacol News 2003; 8(1): 1–7

  9. 9.

    Vieweg WVR, McDaniel NL. Drug-induced QT interval prolongation and torsade de pointes in children and adolescents: part II of a four-part series. Child Adolesc Psycho-pharmacol News 2003; 8(2): 1–5

  10. 10.

    Vieweg WVR, McDaniel NL. Drug-induced QT interval prolongation and torsade de pointes in children and adolescents: part III of a four-part series. Child Adolesc Psycho-pharmacol News 2003; 8(3): 1–4

  11. 11.

    Vieweg WVR, McDaniel NL. Drug-induced QT interval prolongation and torsade de pointes in children and adolescents: part IV of a four-part series. Child Adolesc Psychopharmacol News 2003; 8(4): 1–4

  12. 12.

    Vieweg WVR. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry 2003; 5: 205–15

  13. 13.

    Vieweg WVR, Wood MA. Tricyclic antidepressants, QT interval and torsade de pointes. Psychosomatics 2004; 45: 371–7

  14. 14.

    Vieweg WVR, Schneider RK, Wood MA. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand 2005; 112: 319–23

  15. 15.

    Vieweg WVR, Pandurangi A, Anum EA, et al. Toxicology findings in child and adolescent suicides in Virginia: 1987–2003. Prim Care Companion J Clin Psychiatry 2006; 8: 142–6

  16. 16.

    Fernandez A, Bang SE, Srivathsan K, et al. Cardiovascular side effects of newer antidepressants. Anadolu Kardiyol Derg 2007; 7: 305–9

  17. 17.

    Garratt CJ, Griffith MJ. Electrocardiographic diagnosis of tachycardias. In: Camm AJ, editor. Clinical approaches to tachyarrhythmias. Amonk (NY): Futura Publishing Company, Inc., 1994: 1–53

  18. 18.

    Postema PG, De Jong JSSG, Van der Bilt IAC, et al. Accurate electrocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm 2008; 5: 1015–8

  19. 19.

    Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is “normal”. J Cardiovasc Electrophysiol 2006; 17: 333–6

  20. 20.

    Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353–70

  21. 21.

    Fu EY, Clemo HF, Ellenbogen KA. Acquired QT prolongation: mechanisms and implications. Cardiol Rev 1998; 6: 319–24

  22. 22.

    Viskin S, Justo D, Halkin A, et al. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003; 45: 415–27

  23. 23.

    Tan HL, Hou CJY, Lauer MR, et al. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995; 122: 701–14

  24. 24.

    Yap YG, Camm J. Risk of torsade de pointes with non-cardiac drugs. BMJ 2000; 320: 1158–9

  25. 25.

    Boehnert MT, Lovejoy Jr FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985; 313: 474–9

  26. 26.

    Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovas Dis 2001; 43: 1–45

  27. 27.

    Abdelmawla N, Mitchell AJ. Sudden cardiac death and antipsychotics. Part 1: risk factors and mechanisms. Adv Psychiatr Treat 2006; 12: 35–44

  28. 28.

    Abdelmawla N, Mitchell AJ. Sudden cardiac death and antipsychotics. Part 2: monitoring and prevention. Adv Psychiatr Treat 2006; 12: 100–9

  29. 29.

    Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 2008; 7: 181–94

  30. 30.

    Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013–22

  31. 31.

    Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox® capsules (ziprasidone HCl). 2000 Jul 19 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1.htm [Accessed 2009 Sep 15]

  32. 32.

    Su HM, Chiu HC, Lin TH, et al. Longitudinal study of the ageing trends in QT interval and dispersion in healthy elderly subjects. Age Ageing 2006; 35: 636–8

  33. 33.

    US Food and Drug Administration. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs [online]. Available from URL: http://www.fda.gov/RegulatoryInformation/Guidances/ucm129335.htm [Accessed 2009 Sep 15]

  34. 34.

    Camm AJ, Malik M, Yap YG. Acquired long QT syndrome. London: Blackwell Futura, 2004

  35. 35.

    Browne K, Prystowsky E, Heger JJ, et al. Prolongation of the Q-T interval in man during sleep. Am J Cardiol 1983; 52: 55–9

  36. 36.

    Morganroth J, Brozovich FV, McDonald JT, et al. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991; 67: 774–6

  37. 37.

    Woosley R, Sketch MH. Gender and drug-induced torsade de pointes. ACCEL 30, No. 2. Bethesda (MD): American College of Cardiology, 1998

  38. 38.

    Compton SJ, Lux RL, Ramsey MR, et al. Genetically defined therapy of inherited long-QT syndrome: correction of abnormal repolarization by potassium. Circulation 1996; 94: 1018–22

  39. 39.

    Hatta K, Takahashi T, Nakamura H, et al. Hypokalemia and agitation in acute psychotic patients. Psychiatry Res 1999; 86: 85–8

  40. 40.

    Hatta K, Takahashi T, Nakamura H, et al. Prolonged QT interval in acute psychotic patients. Psychiatry Res 2000; 94: 279–85

  41. 41.

    US Food and Drug Administration Advisory Committee. Zeldox capsules (ziprasidone): summary of efficacy and safety and overall benefit risk relationship. Bethesda (MD): US Food and Drug Administration, 2000 Jul 19

  42. 42.

    Vincent GM. Long QT syndrome. Cardiol Clin 1999; 18: 309–25

  43. 43.

    Schwartz PJ, Periti M, Malliani A. The long QT syndrome. Am Heart J 1975; 89: 378–90

  44. 44.

    Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J 1985; 109: 399–411

  45. 45.

    Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161–7

  46. 46.

    Ray WA, Meader KG. Antipsychotics and sudden death: is thioridazine the only bad actor? Br J Psychiatry 2002; 180: 483–4

  47. 47.

    Ray WA, Chung CP, Murray KT, et al. Atypical anti-psychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225–35

  48. 48.

    Fowler NO, McCall D, Chou T, et al. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 1976; 37: 223–30

  49. 49.

    Ko PT, Gulamhusein S, Kostuk WJ, et al. Torsade de pointes, a common arrhythmia, induced by medication. CMAJ 1982; 127: 368–72

  50. 50.

    Flugelman MY, Pollack S, Hammerman H, et al. Congenital prolongation of Q-T interval: a family study of three generations. Cardiology 1982; 69: 170–4

  51. 51.

    Herrmann HC, Kaplan LM, Bierer BE. QT prolongation and torsade de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 1983; 51: 904–6

  52. 52.

    Davison ET. Amitriptyline-induced torsade de pointes: successful therapy with atrial pacing. J Electrocardiol 1985; 18: 299–302

  53. 53.

    Jerjes Sanchez Diaz C, Garcia Hernandez N, Gonzalez Carmona VM, et al. Helicoidal ventricular tachycardia caused by amitriptyline. Arch Inst Cardiol Mex 1985; 55: 353–6

  54. 54.

    Zee-Cheng CS, Mueller CE, Seifert CF, et al. Haloperidol and torsades de pointes. Ann Intern Med 1985; 102: 418

  55. 55.

    Casazza F, Fiorista F, Rustici A, et al. Torsade de pointes caused by tricyclic antidepressive agents: description of a clinical case. G Ital Cardiol 1986; 16: 1058–61

  56. 56.

    Fayer SA. Torsade de pointes ventricular tachyarrhythmia associated with haloperidol. J Clin Psychopharmacol 1986; 6: 375–6

  57. 57.

    Wilt JL, Minnema AM, Johnson RF, et al. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993; 119: 391–4

  58. 58.

    Metzger E, Friedman R. Prolongation of the corrected QT and torsade de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993; 13: 128–32

  59. 59.

    Hunt N, Stern TA. The association between intravenous haloperidol and torsade de pointes. Psychosomatics 1995; 36: 541–9

  60. 60.

    Di Salvo TG, O’Gara PT. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiology 1995; 18: 285–90

  61. 61.

    Mazur A, Strasberg B, Kusniec J, et al. QT prolongation and polymorphous ventricular tachycardia associated with trazodone-amiodarone combination. Int J Cardiol 1995; 52: 27–9

  62. 62.

    Appleby M, Mbewu A, Clarke B. Fluoxetine and ventricular torsade: is there a link? Int J Cardiol 1995; 49: 178–80

  63. 63.

    Rialan A, Richard M, Deutsch P, et al. Torsade de pointes in a patient under long-term maprotiline therapy: apropos of a case. Ann Cardiol Angeiol (Paris) 1996; 45: 123–5

  64. 64.

    Sharma ND, Rosman HS, Padhi D, et al. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238–40

  65. 65.

    Iglesias E, Esteban E, Zabala S, et al. Tiapride-induced torsade de pointes. Am J Med 2000; 109: 509

  66. 66.

    Douglas PH, Block PC. Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes. Cathet Cardiovasc Intervent 2000; 50: 352–5

  67. 67.

    Lentini S, Rao ML, Schroder R, et al. QT prolongation and torsade de pointes tachycardia during therapy with maprotiline: differential diagnostic and therapeutic aspects. Dtsch Med Wochenschr 2001; 126: 1396–400

  68. 68.

    Kang M, Lesh B, Tampi R, et al. Spotting a silent killer. Current Psychiatry 2004; 3: 75–88

  69. 69.

    Wilting I, Smals OM, Holwerda NJ, et al. QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine [letter]. Am J Psychiatry 2006; 163: 325

  70. 70.

    Letsas K, Korantzopoulos P, Pappas L, et al. QT interval prolongation associated with venlafaxine administration. Int J Cardiol 2006; 109: 116–7

  71. 71.

    Klein-Schwartz W, Lofton AL, Benson BE, et al. Prospective observational multi-poison center study of ziprasidone exposures. Clin Toxicol 2007; 45: 782–6

  72. 72.

    Katagai H, Yasui-Furukori N, Kikuchi A, et al. Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature. Psychiatry Clin Neurosci 2007; 61: 568–70

  73. 73.

    Huang BH, Hsia CP, Chen CY. Sulpiride induced torsade de pointes. Int J Cardiol 2007; 118: e100–2

  74. 74.

    Raviña R, Guteirrez J, Raviña P. Acquired long QT syndrome: long-term electrocardiographic (Holter) recording of torsades de pointes ending in asystole: II. Int J Cardiol 2007; 116: 272–5

  75. 75.

    Mehtonen O-P, Aranko K, Malkonen L, et al. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991; 84: 58–64

  76. 76.

    Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158: 360–9

  77. 77.

    Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048–52

  78. 78.

    Antonelli D, Atar S, Freedberg NA, et al. Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions. Isr Med Assoc J 2005; 7: 163–5

  79. 79.

    Darpö B. Spectrum of drugs prolonging QT interval and the incidence of torsade de pointes. Eur Heart J Supplements 2001; 3Suppl. K: K70–80

  80. 80.

    Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005; 4: 1–6

  81. 81.

    Al-Khatib SM, LaPointe NMA, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003; 289: 2120–7

  82. 82.

    Viskin S, Rosovski U, Sands AJ, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005; 2: 569–74

  83. 83.

    Bai R, Yan GX. Accurate interpretation of the QT interval: a vital task that remains unaccomplished. Heart Rhythm 2005; 2: 575–7

  84. 84.

    Hongo RH, Goldschlager N. Overreliance on computerized algorithms to interpret electrocardiograms. Am J Med 2004; 117: 706–8

  85. 85.

    Roden DM. Keep the QT interval: it is a reliable predictor of ventricular arrhythmias. Heart Rhythm 2008; 5: 1213–5

  86. 86.

    Hondeghem LM. QT prolongation is an unreliable predictor of ventricular arrhythmia. Heart Rhythm 2008; 5: 1210–2

  87. 87.

    Malik M. Is there a physiologic QT/RR relationship? J Cardiovasc Electrophysiol 2002; 13: 1219–21

  88. 88.

    Malik M, Hnatkova K, Schmidt A, et al. Accurately measured and properly heart-rate corrected QTc intervals show little daytime variability. Heart Rhythm 2008; 5: 1424–31

  89. 89.

    Franz MR. Bazett, Fridericia, or Malik? Heart Rhythm 2008; 5: 1432–3

  90. 90.

    Phoon CKL. Mathematic validation of a shorthand rule for calculating QTc. Am J Cardiol 1998; 82: 400–2

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Dr Mehrul Hasnain has received an honorarium from Pfizer Canada Inc. for consultancy services. Dr Anand Pandurangi is on the speakers’ bureau of AstraZeneca, Bristol-Myers Squibb (BMS), Janssen and Pfizer and has received research grants from BMS, Janssen and Eli Lilly. The other authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Correspondence to Dr W. Victor R. Vieweg.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Vieweg, W.V.R., Wood, M.A., Fernandez, A. et al. Proarrhythmic Risk with Antipsychotic and Antidepressant Drugs. Drugs Aging 26, 997–1012 (2009). https://doi.org/10.2165/11318880-000000000-00000

Download citation

Keywords

  • Haloperidol
  • Sudden Cardiac Death
  • Quetiapine
  • Antipsychotic Drug
  • Psychotropic Drug